148549-75-1

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 79047-41-9 2-n-butyl-4-chloro-5-hydroxymethylimidazole 
• 114772-04-2 methyl 2-n-butyl-4-chloro-1-<(4-nitrophenyl)methyl>imidazole-5-acetate 
• 114772-03-1 EXP 9993 
• 114771-99-2 2-Butyl-4-chloro-5-(cyanomethyl]-l-[(4-nitrophenyl)-methyl]imidazole 
• 114799-92-7 2-Butyl-4-chloro-1-[(4-nitrophenyl)methyl]-1H-imidazole-5-methanol 
• 63-91-2 L-phenylalanine 
• 39658-49-6 2,5-dimethoxy-tetrahydro-furan-2-carboxylic acid methyl ester 
• 114772-05-3 methyl 2-butyl-4-chloro-1-(4-aminobenzyl)-imidazole-5-acetate 
• 148549-69-3 (S)-2-(methoxycarbonyl)-α-(phenylmethyl)-1H-pyrrole-1-acetic acid 

Relevant academic research and scientific papers

Anilide derivatives with angiotensin II antagonist properties

This invention relates to anilide derivatives of Formula I STR1 which antagonize the binding of angiotensin II to its receptors. The compounds are useful in the treatment of hypertension, heart failure, glaucoma, and hyperaldosteronism. Methods of making the compounds, novel intermediates useful in the preparation of the compounds, compositions containing the compounds and methods of using them are also covered.

Nonpeptide angiotensin II receptor antagonists. 1. Synthesis and in vitro structure-activity relationships of 4[[[(1H-pyrrol-1- ylacetyl)amino]phenyl]methyl]imidazole derivatives as angiotensin II receptor antagonists

A novel series of non-biphenylyltetrazole angiotensin II receptor antagonists which contain a 1H-pyrrol-1-ylacetyl residue in place of the benzoyl residue in EXP 6803 have been developed. The receptor binding activity of several members of this new series